Last reviewed · How we verify
Xolair injections
Xolair is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.
Xolair is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing it from interacting with high-affinity IgE receptors on mast cells and basophils. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Nasal polyposis.
At a glance
| Generic name | Xolair injections |
|---|---|
| Sponsor | University of California, Los Angeles |
| Drug class | Anti-IgE monoclonal antibody |
| Target | Immunoglobulin E (IgE) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
By sequestering free IgE, Xolair reduces the allergic cascade activation that would normally occur when allergens cross-link IgE-receptor complexes on mast cells and basophils. This prevents the release of inflammatory mediators (histamine, tryptase, leukotrienes) that drive allergic symptoms. The reduction in IgE-mediated signaling is particularly effective in IgE-driven allergic and asthmatic conditions.
Approved indications
- Moderate to severe allergic asthma
- Chronic idiopathic urticaria
- Nasal polyposis
- Food allergy (in combination with oral immunotherapy)
Common side effects
- Injection site reaction
- Headache
- Upper respiratory tract infection
- Arthralgia
- Anaphylaxis
Key clinical trials
- Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
- A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects. (PHASE1)
- A Study to Find a Suitable Dose of Exl-111 for Further Research (PHASE1)
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (PHASE2)
- Omalizumab Weight-Based Dosing Efficacy Trial (PHASE2)
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients (PHASE2)
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients (PHASE3)
- Preventing Asthma in High Risk Kids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xolair injections CI brief — competitive landscape report
- Xolair injections updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI